Lantern Pharma Introduces AI Tool PredictBBB.ai(TM) with 94% Accuracy in Predicting Blood-Brain Barrier Permeability
Lantern Pharma's new AI module, predictBBB.ai(TM), significantly enhances the prediction of small molecules' ability to cross the blood-brain barrier, addressing a major challenge in drug development.
Lantern Pharma (NASDAQ: LTRN), a leader in AI-driven oncology drug development, has recently unveiled predictBBB.ai(TM), a groundbreaking public AI module designed to predict the permeability of small molecules through the blood-brain barrier (BBB) with an impressive 94% accuracy. This innovation is set to revolutionize the pharmaceutical industry, where the challenge of developing drugs capable of crossing the BBB has long been a significant hurdle, with only 2–6% of small molecules currently able to do so.
The predictBBB.ai(TM) platform, built upon billions of molecular data points from Lantern Pharma's proprietary data lake, not only boasts high accuracy but also achieves 95% sensitivity and 89% specificity. Its performance ranks it among the top on the Therapeutic Data Commons Leaderboard, thanks to its use of synthetic data augmentation and advanced molecular representation techniques that allow for real-time compound processing. This development comes at a time when the BBB technologies market is experiencing rapid growth, projected to expand from $1.4 billion in 2023 to $9.85 billion by 2032, highlighting the urgent clinical demand for such solutions.
For more details on this innovative tool, visit https://ibn.fm/pRgxt. Lantern Pharma's commitment to leveraging AI and machine learning in oncology drug development is evident in their proprietary RADR(R) platform, which utilizes over 100 billion oncology-focused data points and a library of more than 200 advanced ML algorithms. This approach not only accelerates the drug discovery process but also addresses billion-dollar challenges in oncology, offering hope for more effective treatments for cancer patients worldwide.
The introduction of predictBBB.ai(TM) marks a significant milestone in the quest to overcome the blood-brain barrier, a critical obstacle in the development of treatments for neurological diseases and cancers. By providing a tool that accurately predicts BBB permeability, Lantern Pharma is paving the way for the development of new therapies that could significantly improve patient outcomes. For further information on Lantern Pharma and their innovative solutions, visit https://ibn.fm/LTRN.